image credit- shutterstock
AdvanCell, a radiopharmaceutical company specialising in targeted alphaherapias, has announced the expansion of the scope and scale of its strategic collaboration with Eli Lilly and Company for the research and development of innovative treatments for various cancers.
Under the new agreement, the parties will leverage AdvanCell's Pb-212 production technology and radionuclide development infrastructure, as well as Lilly's drug candidate programs and deep drug development expertise, to facilitate the development and accelerate clinical advancement of an expanded portfolio of targeted alpha therapies.
Australia-based AdvanCell's competitive advantage in technology development and the infrastructure put in place to accelerate early-stage clinical trials in Australia enable AdvanCell to rapidly develop and advance novel Pb-212-containing radiotherapies from discovery to clinical trials.
Andrew Adamovich, CEO of AdvanCell said, "By combining our groundbreaking isotope production capabilities, our team's expertise and infrastructure with Lilly's pharmaceutical and oncology expertise and global reach, we aim to bring transformative treatments to patients with difficult-to-treat cancers. We are particularly pleased to continue and expand our existing relationship.
Jacob Van Naarden, President of Lilly Oncology, added, "The partnership with AdvanCell is part of our drive to develop innovative radiopharmaceuticals.
